Wuxi Biologics Unveils Scaled Global CRDMO Platform Advancing Biologics Development

Reuters01-11

Wuxi Biologics Unveils Scaled Global CRDMO Platform Advancing Biologics Development

Wuxi Biologics (Cayman) Inc. has released a presentation outlining its scaled CRDMO (Contract Research, Development, and Manufacturing Organization) platform, which supports the global advancement of biologics. The presentation details the company’s comprehensive end-to-end offerings across the biologics lifecycle, including services in monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, antibody drug conjugates, viral vaccines, oncolytic viruses, virus-like particles, recombinant proteins, and antibody fragments. Key highlights include support for over 600 IND submissions globally, 25 commercial programs, and 74 Phase III projects. The company reports maintaining high reliability metrics, with a 98.3% DS success rate and a 99.6% DP success rate, and a 100% success rate in regulatory inspections by the FDA, EMA, and NMPA. Wuxi Biologics emphasizes its flexible service model, enabling global clients to access tailored contract services across research, development, and manufacturing. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602559599?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-11 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602559599","market":"nz","top_or_hot":-1,"title":"Wuxi Biologics Unveils Scaled Global CRDMO Platform Advancing Biologics Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Wuxi Biologics Unveils Scaled Global CRDMO Platform Advancing Biologics Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/WXIBF\">Wuxi Biologics (Cayman) Inc</a>. has released a presentation outlining its scaled CRDMO (Contract Research, Development, and Manufacturing Organization) platform, which supports the global advancement of biologics. The presentation details the company’s comprehensive end-to-end offerings across the biologics lifecycle, including services in monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, antibody drug conjugates, viral vaccines, oncolytic viruses, virus-like particles, recombinant proteins, and antibody fragments. Key highlights include support for over 600 IND submissions globally, 25 commercial programs, and 74 Phase III projects. The company reports maintaining high reliability metrics, with a 98.3% DS success rate and a 99.6% DP success rate, and a 100% success rate in regulatory inspections by the FDA, EMA, and NMPA. Wuxi Biologics emphasizes its flexible service model, enabling global clients to access tailored contract services across research, development, and manufacturing. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/WXXWY\">Wuxi Biologics (Cayman)</a> Inc. published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wuxi Biologics Unveils Scaled Global CRDMO Platform Advancing Biologics Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuxi Biologics Unveils Scaled Global CRDMO Platform Advancing Biologics Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-11 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Wuxi Biologics Unveils Scaled Global CRDMO Platform Advancing Biologics Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/WXIBF\">Wuxi Biologics (Cayman) Inc</a>. has released a presentation outlining its scaled CRDMO (Contract Research, Development, and Manufacturing Organization) platform, which supports the global advancement of biologics. The presentation details the company’s comprehensive end-to-end offerings across the biologics lifecycle, including services in monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, antibody drug conjugates, viral vaccines, oncolytic viruses, virus-like particles, recombinant proteins, and antibody fragments. Key highlights include support for over 600 IND submissions globally, 25 commercial programs, and 74 Phase III projects. The company reports maintaining high reliability metrics, with a 98.3% DS success rate and a 99.6% DP success rate, and a 100% success rate in regulatory inspections by the FDA, EMA, and NMPA. Wuxi Biologics emphasizes its flexible service model, enabling global clients to access tailored contract services across research, development, and manufacturing. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/WXXWY\">Wuxi Biologics (Cayman)</a> Inc. published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0307460666.USD","symbol_name":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL4tjbN4:1","article_id":"2602559599","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602559599","pubTimestamp":1768135968,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Wuxi Biologics  Inc. has released a presentation outlining its scaled CRDMO  platform, which supports the global advancement of biologics. The presentation details the company’s comprehensive end-to-end offerings across the biologics lifecycle, including services in monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, antibody drug conjugates, viral vaccines, oncolytic viruses, virus-like particles, recombinant proteins, and antibody fragments. Key highlights include support for over 600 IND submissions globally, 25 commercial programs, and 74 Phase III projects. The company reports maintaining high reliability metrics, with a 98.3% DS success rate and a 99.6% DP success rate, and a 100% success rate in regulatory inspections by the FDA, EMA, and NMPA. Wuxi Biologics emphasizes its flexible service model, enabling global clients to access tailored contract services across research, development, and manufacturing. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1521":"挪威政府全球养老基金持仓","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0823426480.USD":"法巴中国股票经典Dis","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","02269":"药明生物","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0823426308.USD":"法巴中国股票基金","LU1720050803.USD":"安联全方位中国股票基金","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0359201612.USD":"贝莱德中国基金A2","BK1589":"北水核心资产","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0051755006.USD":"摩根大通中国A (dist)","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","BK1610":"ETF&股票定投概念","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc"},"translate_title":"药明生物推出规模化全球CRDMO平台推进生物制剂开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":0.9},"content_text":"Wuxi Biologics Unveils Scaled Global CRDMO Platform Advancing Biologics Development\n    \n\nWuxi Biologics (Cayman) Inc. has released a presentation outlining its scaled CRDMO (Contract Research, Development, and Manufacturing Organization) platform, which supports the global advancement of biologics. The presentation details the company’s comprehensive end-to-end offerings across the biologics lifecycle, including services in monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, antibody drug conjugates, viral vaccines, oncolytic viruses, virus-like particles, recombinant proteins, and antibody fragments. Key highlights include support for over 600 IND submissions globally, 25 commercial programs, and 74 Phase III projects. The company reports maintaining high reliability metrics, with a 98.3% DS success rate and a 99.6% DP success rate, and a 100% success rate in regulatory inspections by the FDA, EMA, and NMPA. Wuxi Biologics emphasizes its flexible service model, enabling global clients to access tailored contract services across research, development, and manufacturing. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602559599","isCrawlerRequest":true}